Adavosertib

Adavosertib
Names
	IUPAC name 1-[6-(2-Hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one
	Other names AZD1775; MK-1775
Identifiers
CAS Number	955365-80-7;
3D model (JSmol)	Interactive image;
ChEBI	CHEBI:91414;
ChEMBL	ChEMBL1976040;
ChemSpider	24808590;
ECHA InfoCard	100.205.373
IUPHAR/BPS	7702;
KEGG	D11361;
PubChem CID	24856436;
UNII	K2T6HJX3I3;
CompTox Dashboard (EPA)	DTXSID30241868 ;
	InChI InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31) Key: BKWJAKQVGHWELA-UHFFFAOYSA-N;
	SMILES CN1CCN(CC1)c2ccc(Nc3ncc4C(=O)N(CC=C)N(c5cccc(n5)C(C)(C)O)c4n3)cc2;
Properties
Chemical formula	C27H32N8O2
Molar mass	500.607 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	Infobox references

Adavosertib (development codes AZD1775, MK-1775) is an experimental anti-cancer drug candidate. It is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity.[1] It is being developed by AstraZeneca.[2]It is being investigated as a treatment for pancreatic cancer with phase 1 trial.[3][4] University of Michigan researchers are as of 2019 planning a phase 2 study.[5]

References

"NCI Drug Dictionary". National Cancer Institute. 2 February 2011. Retrieved 17 August 2019.
"AZD1775 | AstraZeneca Open Innovation". openinnovation.astrazeneca.com. Retrieved 17 August 2019.
"Early Activity in Pancreatic Cancer With New Drug". www.medpagetoday.com. 16 August 2019. Retrieved 17 August 2019.
Cuneo, KC; Morgan, MA; Sahai, V; Schipper, MJ; Parsels, LA; Parsels, JD; Devasia, T; Al-Hawaray, M; Cho, CS; Nathan, H; Maybaum, J; Zalupski, MM; Lawrence, TS (9 August 2019). "Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer". Journal of Clinical Oncology. 37 (29): 2643–2650. doi:10.1200/JCO.19.00730. PMID 31398082.
"AstraZeneca drug heads to phase 2 in pancreatic cancer after small trial extends survival". FierceBiotech. Retrieved 17 August 2019.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "NCI Drug Dictionary". National Cancer Institute. 2 February 2011. Retrieved 17 August 2019.

[2] "AZD1775 | AstraZeneca Open Innovation". openinnovation.astrazeneca.com. Retrieved 17 August 2019.

[3] "Early Activity in Pancreatic Cancer With New Drug". www.medpagetoday.com. 16 August 2019. Retrieved 17 August 2019.

[4] Cuneo, KC; Morgan, MA; Sahai, V; Schipper, MJ; Parsels, LA; Parsels, JD; Devasia, T; Al-Hawaray, M; Cho, CS; Nathan, H; Maybaum, J; Zalupski, MM; Lawrence, TS (9 August 2019). "Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer". Journal of Clinical Oncology. 37 (29): 2643–2650. doi:10.1200/JCO.19.00730. PMID 31398082.

[5] "AstraZeneca drug heads to phase 2 in pancreatic cancer after small trial extends survival". FierceBiotech. Retrieved 17 August 2019.